Diabetes Monitoring Target healthcare systems and clinics focused on diabetes care with the G1A Rapid Diabetes Monitoring Index Test, highlighting its patented monthly monitoring capability to support recurring device sales and consumables.

POC/OTC Focus Position the product line for point-of-care and over-the-counter markets where rapid, quantitative diagnostics are valued, leveraging the existing platform to expand into adjacent rapid-test segments.

Clinical Adjacent Leverage proximity to major diabetes players and academic hubs by partnering with healthcare providers, labs, and research centers to pilot and validate rapid diagnostic tests, accelerating adoption and reimbursement discussions.

Growth Tiers Target mid-sized biotechs and medical-device firms with complementary capabilities to co-develop or white-label rapid-test platforms, opening avenues for joint ventures or licensing deals as the company scales.

Digital Enablement Promote integrated software and analytics capabilities (cloud-based dashboards, dashboards for test results) to enhance data-driven diabetes management, appealing to providers seeking value-based outcomes and add-on services.